WallStSmart

Eterna Therapeutics Inc (ERNA)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 60642200% more annual revenue ($606.42M vs $1,000). ERNA leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

ERNA

Avoid

21

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 6.7Quality: 5.8
Piotroski: 1/9

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ERNAUndervalued (+99.9%)

Margin of Safety

+99.9%

Fair Value

$382.98

Current Price

$0.21

$382.77 discount

UndervaluedFair: $382.98Overvalued

Intrinsic value data unavailable for INSM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ERNA2 strengths · Avg: 9.5/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.159/10

Conservative balance sheet, low leverage

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ERNA4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.20M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ERNA

The strongest argument for ERNA centers on Price/Book, Debt/Equity.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : ERNA

The primary concerns for ERNA are EPS Growth, Market Cap, Profit Margin.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

ERNA profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.

ERNA carries more volatility with a beta of 6.87 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

ERNA generates stronger free cash flow (-1M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 21/100). ERNA offers better value entry with a 99.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eterna Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?